Autonomix Medical, Inc. (AMIX)
| Market Cap | 4.54M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.03M |
| Shares Out | 1.15M |
| EPS (ttm) | -15.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,308,762 |
| Open | 4.560 |
| Previous Close | 3.300 |
| Day's Range | 3.630 - 4.580 |
| 52-Week Range | 2.880 - 152.000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 11, 2025 |
About AMIX
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. It has an agreement with NoiseFi... [Read more]
Financial Performance
Financial StatementsNews
Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company's Proprietary Catheter-Based Technology
Growing global patent portfolio to over 120 patents with 80 issued patents and over 40 pending patent applications Previously completed preclinical study evaluating targeted nerve ablation demonstrate...
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
THE WOODLANDS, TX, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to rev...
Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025
First-in-class catheter-based sensing technology designed to sense neuronal signals that indicate pain or disease and destroy those nerves at the source
Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option
THE WOODLANDS, TX, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treat...
Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering
THE WOODLANDS, TX, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treat...
Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder group went to zero opioid use at 4-6 week...
Autonomix Medical, Inc.'s Dr. Robert Schwartz Discusses What Positive 4-6 Week Follow-Up Data Means from Lead-In Patients in Ongoing Human Clinical Trial
Access the Virtual Investor “What This Means” Segment here
Crude Oil Tumbles Over 5%; Autonomix Medical Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Monday.
Why Is Nao-Cap Neurology Focused Autonomix Medical Stock Trading Higher On Monday?
Autonomix Medical, Inc. AMIX stock is trading higher on Monday, with a strong session volume of 6.11 million compared to the average volume of 22.87 thousand, as per data from Benzinga Pro.
Autonomix Medical, Inc. to Participate in a Virtual Investor “What This Means” Segment on Wednesday, October 30th
THE WOODLANDS, TX, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treat...
Autonomix Announces Reverse Stock Split
THE WOODLANDS, TX, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treat...
Autonomix Medical, Inc. to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
Live webcast fireside chat on Tuesday, October 15 th at 2:30 PM ET THE WOODLANDS, TX, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical...
Autonomix Selected to Present at the 2024 Octane Medical Innovation Forum
THE WOODLANDS, TX, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted trea...
Autonomix Medical, Inc. to Present at H.C. Wainwright 26th Annual Global Investment Conference
THE WOODLANDS, TX, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to rev...
Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2024 CIRSE Annual Congress
Presentation to discuss latest developments in future AI applications in interventional radiology, specifically highlighting the early results from the Company's ongoing proof-of-concept (PoC) human c...
Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones
First-in-class catheter-based sensing and ablation technology that targets neural signals that indicate pain or disease and destroys them at the source
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
Live webcast on Wednesday, July 24 th at 4:00 PM ET THE WOODLANDS, TX, July 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company...
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Covering Technology License Agreement
Brad Hauser, Chief Executive Officer of Autonomix, discusses the Company's agreement to license FDA-cleared ablation technology from RF Innovations, Inc.
Autonomix Medical, Inc. (NASDAQ: AMIX) Reviews Positive Results Seen in Pancreatic Cancer Pain Trial in Virtual Investor “What This Means” Segment
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses preliminary positive results from the first five “lead-in” patients in the Company's ongoing human clinical trial
Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer
Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix...
Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial
Company plans to release topline results from “lead-in” patients (n=5) imminently THE WOODLANDS, TX, June 03, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Compa...
Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update
Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system
Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer
Results from the preclinical study demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass
Autonomix to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Live webcast on Wednesday, May 1 st at 3:20 PM ET THE WOODLANDS, TX, April 24, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company ...
Autonomix Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related Pain
Patent portfolio with over 100 patents, issued and pending, protects technology targeting a $100 billion market opportunity